Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Viewpoint
  • Published:

Should cholinesterase inhibitors be used to treat Alzheimer's disease?

Nature Clinical Practice Neurology volume 2, pages 118–119 (2006)Cite this article

Improvements in cognitive functions and clinical global state have been reported consistently in randomized controlled trials of CHOLINESTERASE INHIBITORS (ChEIs) in patients with Alzheimer's disease. Whether these drugs provide meaningful benefit to patients and their caregivers remains controversial, however, and the proper clinical role of these drugs continues to be a focus of debate.

A family with a senior member who develops Alzheimer-type dementia presents a constellation of challenges, resources, personalities, and culture. Dementia arrives insidiously. Complex questions arise as the patient's personal responsibility fades. As abilities decline—imperceptibly and cumulatively—ever-increasing amounts of care are needed. How these care needs are acknowledged and met is as individual as any family or intimate relationship. The process is similar in non-family contexts, although perhaps more isolated or institutionalized. Burdens are comprehensive and personal.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Rogers SL and Friedhoff LT (1996) The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double Blind, Placebo-Controlled Trial, The Donepezil Study Group. Dementia 7: 293–303

    CAS  PubMed  Google Scholar 

  2. Burns A et al. (1999) The effects of donepezil in Alzheimer's disease—results from a multinational trial. Dement Geriatr Cogn Disord 10: 237–244

    Article  CAS  Google Scholar 

  3. Rogers SL et al. (1998) A 24-week, double blind, placebo-controlled trial of donepezil in-patients with Alzheimer's disease. Donepezil Study Group. Neurology 50: 136–145

    Article  CAS  Google Scholar 

  4. Rogers SL et al. (1998) Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 158: 1021–1031

    Article  CAS  Google Scholar 

  5. AD2000 Collaborative Group (2004) Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomized double-blind trial. Lancet 363: 2105–2115

  6. Geldmacher DS et al. (2003) Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc 51: 937–944

    Article  Google Scholar 

  7. Schneider LS et al. (2004) Delay in nursing home placement with donepezil. J Am Geriatr Soc 52: 1024–1026

    Article  Google Scholar 

  8. Finucane TE (2004) Another advertisement for donepezil. J Am Geriatr Soc 52: 843

  9. Cummings JL (2004) Drug therapy in Alzheimer disease. N Engl J Med 351: 1911–1912

    Article  Google Scholar 

  10. Kaduszkiewicz H et al. (2005) Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomized clinical trials. BMJ 331: 321–323

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors acknowledge that the views expressed in this article represent their own opinions and should not be construed as representing those of the Navy, the Department of Defense, or the US Government.

Author information

Authors and Affiliations

  1. Professor of Medicine in the Division of Geriatric Medicine at Johns Hopkins, Baltimore, MD, USA

    Thomas E Finucane

  2. practices medicine and geriatrics at the National Naval Medical Center and heads its Responsible Conduct of Research Department, Bethesda, MD, USA

    John R Gilstad

Authors
  1. Thomas E Finucane
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John R Gilstad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas E Finucane.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Finucane, T., Gilstad, J. Should cholinesterase inhibitors be used to treat Alzheimer's disease?. Nat Rev Neurol 2, 118–119 (2006). https://doi.org/10.1038/ncpneuro0130

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneuro0130

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing